EFFICACY AND SAFETY OF IRON (III)–HYDROXIDE SUCROSE COMPLEX IN CORRECTION OF ANEMIA STAGE 5D CHRONIC KIDNEYDISEASE HEMODIALYSIS PATIENTS NOT TREATED BY ERYTHROPOIESIS–STIMULATING AGENTS (PROSPECTIVEANALYSIS)
Abstract
The aim of study was to evaluat the efficacy and safety ofSUFER® (iron (III) sucrose complex) in correction of anemia stage 5D chronic kidney disease hemodialysis patients.
Methods. This study included thirty patients undergoing regular hemodialysis (mean age 48,81±3,24 years, mean duration of dialysis 30,43±9,25 months) with renal anemia and iron deficiency. All patients were treated with SUFER® intravenously 200 mg three times a week. Correction dose was determined according to the manufacturer’s recommendations.
Results. Mean level offerritin was significantly increased from 125,15 ± 21,46 ng / ml to 375,56 ± 64,12 ng / ml (p <0,001), transferrin saturation – from 17,48 ± 2,71% to 38,21 ± 4,90 ng / ml (p <0,001). 23 (76.67%) patients achieved target levels offerritin and transferrin, 12 (40% ) adverse events.
Conclusions. SUFER® is effective and safety drug in dialysis patients.
Downloads
References
Covic A. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi–centre, open–label, clinical study / A. Covic, G. Mircescu // Nephrol. Dial. Transplant. – 2010. – Vol. 25. – P. 2722–2730.
Hor Walter H. Anaemia management and mortality risk in chronic kidney disease / Walter H. Hr // Nature Reviews Nephrology. – 2013. – Vol. 9. – P. 291–301.
Hypersensitivity reactions and deaths associated with intravenous iron preparations / G. R. Bailie, J. A. Clark, C. E. Lane, P. L. Lane // Nephrol Dial Transplant. – 2005. – Vol. 20. –P. 1443–1449.
Intravenous versus oral iron supplementation for the treatment of anemia in CKD: systematic review and meta–analysis / B. Rozen–Zvi, A. Gafter–Gvili, M. Paul, L. Leibovici, O. Shpilberg, U. Gafter // Am J Kidney Dis. – 2008. – Vol. 52. – P. 897–906.
Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl. – 2012. – № 2. – Р. 279–335.
Meta–analysis of efficacy and safety of intravenous ferric carboxymaltose (Ferinject) from clinical trial reports and published trial data [Електронний ресурс] / R. A. Moore, H. Gaskell, P. Rose, J. Allan // BMC Blood Disorders 2011, 11:4 http://www.biomedcentral. com/1471–2326/11/4.
Systematic review of the impact of erythropoiesis– stimulating agents on fatigue in dialysis patients / K. L. Johansen, F. O. Finkelstein, D. A. Revicki et all. // Nephrol. Dial. Transplant. – 2012. – Vol. 27, Issue 6. – P. 2418–2425.
